- Home
- YALA vs GYRE Comparison
YALA vs GYRE Comparison
Compare YALA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YALA
- GYRE
- Stock Information
- Founded
- YALA 2016
- GYRE 2002
- Country
- YALA United Arab Emirates
- GYRE United States
- Employees
- YALA N/A
- GYRE N/A
- Industry
- YALA Computer Software: Programming Data Processing
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- YALA Technology
- GYRE Health Care
- Exchange
- YALA Nasdaq
- GYRE Nasdaq
- Market Cap
- YALA 1.1B
- GYRE 897.1M
- IPO Year
- YALA 2020
- GYRE N/A
- Fundamental
- Price
- YALA $7.75
- GYRE $7.64
- Analyst Decision
- YALA
- GYRE
- Analyst Count
- YALA 0
- GYRE 0
- Target Price
- YALA N/A
- GYRE N/A
- AVG Volume (30 Days)
- YALA 413.8K
- GYRE 153.7K
- Earning Date
- YALA 08-11-2025
- GYRE 08-12-2025
- Dividend Yield
- YALA N/A
- GYRE N/A
- EPS Growth
- YALA 8.53
- GYRE N/A
- EPS
- YALA 0.77
- GYRE 0.02
- Revenue
- YALA $344,824,034.00
- GYRE $100,643,000.00
- Revenue This Year
- YALA $8.87
- GYRE $21.04
- Revenue Next Year
- YALA $5.56
- GYRE $89.64
- P/E Ratio
- YALA $10.43
- GYRE $93.27
- Revenue Growth
- YALA 6.40
- GYRE N/A
- 52 Week Low
- YALA $3.71
- GYRE $6.11
- 52 Week High
- YALA $8.29
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- YALA 59.37
- GYRE 48.87
- Support Level
- YALA $7.07
- GYRE $7.09
- Resistance Level
- YALA $8.28
- GYRE $7.62
- Average True Range (ATR)
- YALA 0.27
- GYRE 0.37
- MACD
- YALA 0.07
- GYRE 0.05
- Stochastic Oscillator
- YALA 58.27
- GYRE 48.72
About YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.